Castle Biosciences, Inc. (CSTL)
| Market Cap | 670.60M +36.3% |
| Revenue (ttm) | 339.92M -2.1% |
| Net Income | -12.83M |
| EPS | -0.44 |
| Shares Out | 30.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 242,895 |
| Open | 21.12 |
| Previous Close | 21.26 |
| Day's Range | 21.10 - 22.18 |
| 52-Week Range | 14.59 - 44.28 |
| Beta | 1.11 |
| Analysts | Strong Buy |
| Price Target | 45.88 (+107.51%) |
| Earnings Date | May 6, 2026 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $45.88, which is an increase of 107.51% from the latest price.
News
Castle Biosciences price target lowered to $40 from $50 at BTIG
BTIG lowered the firm’s price target on Castle Biosciences (CSTL) to $40 from $50 and keeps a Buy rating on the shares. The company delivered a solid 10% revenue beat…
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
FRIENDSWOOD, Texas, May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executiv...
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions FRIENDSWOOD, Texas, May 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a ...
Castle Biosciences reports Q1 EPS , consensus (49c)
Reports Q1 revenue $83.7M, consensus $79.23M. “The Castle Biosciences (CSTL) team delivered outstanding results to start 2026, delivering $83.7M in revenue,” said CEO Derek Maetzold. “Our momentum thi...
Castle Biosciences raises 2026 revenue view to $345M-$355M from $340M-350M
2026 revenue consensus $345.73M.
Castle Biosciences Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and test volume growth, with record months for core products and improved margins. Full-year guidance was raised, and new clinical data reinforced product value. Reimbursement clarity for AdvanceAD-Tx is expected by Q3, with material revenue anticipated in 2027–2028.
Castle Biosciences Slides: Q1 2026
Castle Biosciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Castle Biosciences Quarterly report: Q1 2026
Castle Biosciences has published its Q1 2026 quarterly earnings report on May 6, 2026.
Castle Biosciences Earnings release: Q1 2026
Castle Biosciences released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Castle Biosciences Reports First Quarter 2026 Results
Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ®) increased 36% over Q1 2025 Raising full-year 2026 revenue g...
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
Longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus continue to advance awareness and education throughout M...
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus
Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one ...
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk ...
Castle Biosciences price target lowered to $40 from $50 at Canaccord
Canaccord analyst Kyle Mikson lowered the firm’s price target on Castle Biosciences (CSTL) to $40 from $50 and keeps a Buy rating on the shares. The firm updated its model…
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will re...
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
FRIENDSWOOD, Texas, April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has rec...
Castle Biosciences Proxy statement: Proxy filing
Castle Biosciences filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Castle Biosciences Proxy statement: Proxy filing
Castle Biosciences filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Castle Biosciences to present new data from DecisionDx-Melanoma test at AAD
Castle Biosciences (CSTL) will present new data at the 2026 American Academy of Dermatology Annual Meeting, taking place March 27-31 in Denver, demonstrating that its DecisionDx-Melanoma test refines ...
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee...
Castle Biosciences Transcript: Status update
The DECIDE study confirms DecisionDx-Melanoma's strong predictive value for sentinel lymph node positivity and recurrence risk, enabling precise risk stratification and safe de-escalation of care for low-risk melanoma patients. The test outperforms competing assays and is widely adopted in clinical practice, supporting its case for guideline inclusion.
Castle Biosciences Slides: Status update
Castle Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
Castle announces publication of DecisionDx-Melanoma’s i31-SLNB study results
Castle Biosciences (CSTL) announced the publication of results from the largest prospective, multicenter study to date evaluating DecisionDx-Melanoma’s integrated sentinel lymph node biopsy test resul...
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
Castle today announced the publication of results from a prospective, multicenter study evaluating DecisionDx-Melanoma's integrated SLNB test result.
Castle Biosciences announces new data from study evaluating i31SLNB
Castle Biosciences (CSTL) announced new data from the largest prospective multicenter study to date evaluating DecisionDx-Melanoma’s integrated sentinel lymph node biopsy, i31SLNB, test result. The st...